Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.

Standard

Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy. / Hammerer, P; Graefen, M; Henke, R P; Haese, Alexander; Palisaar, J; Huland, E; Huland, H.

in: ANTICANCER RES, Jahrgang 20, Nr. 6, 6, 2000, S. 5253-5255.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Hammerer, P, Graefen, M, Henke, RP, Haese, A, Palisaar, J, Huland, E & Huland, H 2000, 'Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.', ANTICANCER RES, Jg. 20, Nr. 6, 6, S. 5253-5255. <http://www.ncbi.nlm.nih.gov/pubmed/11326705?dopt=Citation>

APA

Hammerer, P., Graefen, M., Henke, R. P., Haese, A., Palisaar, J., Huland, E., & Huland, H. (2000). Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy. ANTICANCER RES, 20(6), 5253-5255. [6]. http://www.ncbi.nlm.nih.gov/pubmed/11326705?dopt=Citation

Vancouver

Hammerer P, Graefen M, Henke RP, Haese A, Palisaar J, Huland E et al. Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy. ANTICANCER RES. 2000;20(6):5253-5255. 6.

Bibtex

@article{a70406dfe5d04990be6d55ac9aa1a523,
title = "Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.",
abstract = "BACKGROUND: The aim of this study was the longitudinal comparison of % f-PSA in patients before radical prostatectomy and after PSA relapse. Is % f-PSA a consistent tumor specific parameter or does this ratio change during untreated tumor progression? MATERIALS AND METHODS: In this study 41 out of 420 patients with untreated increasing PSA-progression (> 0.5 ng/ml) were analysed. Patients with neoadjuvant or adjuvant hormonal therapy were excluded. T-PSA were f-PSA were analyzed by Immulite DPC (Diagnostic Products Coop., CA) and Abbott Axsym (Abbott Park, Il, USA). RESULTS: Pre-operative % f-PSA ratio was 10.6% (range 4.6-22%; Std. dev.: 4.9); T-PSA concentration was 26.4 ng/ml (range 5.5-10.2 ng/ml Std. dev.: 20.3). In men with PSA relapse after radical prostatectomy % f-PSA ratio was 14.73% (range 2.2-4.5% Std. dev.: 9.7). Repeated post-operative % f-PSA measurements resulted in 12.94% f-PSA (range 2.7-3.8% Std. dev.: 9.9%) with a regression of R = 0.57. All men with pre-operative elevated % f-PSA (> 15%) had post-operative elevated % f-PSA. CONCLUSIONS: The data indicates that post-operative % f-PSA is a constant tumor specific parameter in men with untreated PSA relapse after radical prostatectomy. Post-operative % f-PSA was higher compared with pre-operative % f-PSA concentrations. No correlation with Gleason score or pathological stage was found.",
author = "P Hammerer and M Graefen and Henke, {R P} and Alexander Haese and J Palisaar and E Huland and H Huland",
year = "2000",
language = "Deutsch",
volume = "20",
pages = "5253--5255",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

RIS

TY - JOUR

T1 - Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.

AU - Hammerer, P

AU - Graefen, M

AU - Henke, R P

AU - Haese, Alexander

AU - Palisaar, J

AU - Huland, E

AU - Huland, H

PY - 2000

Y1 - 2000

N2 - BACKGROUND: The aim of this study was the longitudinal comparison of % f-PSA in patients before radical prostatectomy and after PSA relapse. Is % f-PSA a consistent tumor specific parameter or does this ratio change during untreated tumor progression? MATERIALS AND METHODS: In this study 41 out of 420 patients with untreated increasing PSA-progression (> 0.5 ng/ml) were analysed. Patients with neoadjuvant or adjuvant hormonal therapy were excluded. T-PSA were f-PSA were analyzed by Immulite DPC (Diagnostic Products Coop., CA) and Abbott Axsym (Abbott Park, Il, USA). RESULTS: Pre-operative % f-PSA ratio was 10.6% (range 4.6-22%; Std. dev.: 4.9); T-PSA concentration was 26.4 ng/ml (range 5.5-10.2 ng/ml Std. dev.: 20.3). In men with PSA relapse after radical prostatectomy % f-PSA ratio was 14.73% (range 2.2-4.5% Std. dev.: 9.7). Repeated post-operative % f-PSA measurements resulted in 12.94% f-PSA (range 2.7-3.8% Std. dev.: 9.9%) with a regression of R = 0.57. All men with pre-operative elevated % f-PSA (> 15%) had post-operative elevated % f-PSA. CONCLUSIONS: The data indicates that post-operative % f-PSA is a constant tumor specific parameter in men with untreated PSA relapse after radical prostatectomy. Post-operative % f-PSA was higher compared with pre-operative % f-PSA concentrations. No correlation with Gleason score or pathological stage was found.

AB - BACKGROUND: The aim of this study was the longitudinal comparison of % f-PSA in patients before radical prostatectomy and after PSA relapse. Is % f-PSA a consistent tumor specific parameter or does this ratio change during untreated tumor progression? MATERIALS AND METHODS: In this study 41 out of 420 patients with untreated increasing PSA-progression (> 0.5 ng/ml) were analysed. Patients with neoadjuvant or adjuvant hormonal therapy were excluded. T-PSA were f-PSA were analyzed by Immulite DPC (Diagnostic Products Coop., CA) and Abbott Axsym (Abbott Park, Il, USA). RESULTS: Pre-operative % f-PSA ratio was 10.6% (range 4.6-22%; Std. dev.: 4.9); T-PSA concentration was 26.4 ng/ml (range 5.5-10.2 ng/ml Std. dev.: 20.3). In men with PSA relapse after radical prostatectomy % f-PSA ratio was 14.73% (range 2.2-4.5% Std. dev.: 9.7). Repeated post-operative % f-PSA measurements resulted in 12.94% f-PSA (range 2.7-3.8% Std. dev.: 9.9%) with a regression of R = 0.57. All men with pre-operative elevated % f-PSA (> 15%) had post-operative elevated % f-PSA. CONCLUSIONS: The data indicates that post-operative % f-PSA is a constant tumor specific parameter in men with untreated PSA relapse after radical prostatectomy. Post-operative % f-PSA was higher compared with pre-operative % f-PSA concentrations. No correlation with Gleason score or pathological stage was found.

M3 - SCORING: Zeitschriftenaufsatz

VL - 20

SP - 5253

EP - 5255

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 6

M1 - 6

ER -